Inhibitor Therapeutics Inc
OTC:INTI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Inhibitor Therapeutics Inc
Current Portion of Long-Term Debt
Inhibitor Therapeutics Inc
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Inhibitor Therapeutics Inc
OTC:INTI
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Current Portion of Long-Term Debt
$6.1B
|
CAGR 3-Years
14%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
12%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Current Portion of Long-Term Debt
$2.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
0%
|
CAGR 10-Years
11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Current Portion of Long-Term Debt
$4.6B
|
CAGR 3-Years
42%
|
CAGR 5-Years
119%
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Inhibitor Therapeutics Inc
Glance View
Inhibitor Therapeutics, Inc. engages in the discovery, development, and commercialization of therapeutics for patients with cancer. The company is headquartered in Tampa, Florida and currently employs 1 full-time employees. The firm is focused on developing and commercializing therapeutics for patients with certain cancers and certain non-cancerous proliferation disorders. The firm is focused on development of its lead product, SUBA-Itraconazole, an oral formulation of anti-fungal drug, Itraconazole, for any prostate cancer, prostatic intraepithelial neoplasia and benign prostatic hyperplasia; lung cancer and atypical adenomatous hyperplasia. SUBA-Itraconazole is designed to enable absorption and reduced variability compared to generic itraconazole. The company is developing SUBA-Itraconazole prostate to address the unmet need for men with late-stage, metastatic castrate-resistant prostate cancer (mCRPC). The company is also developing SUBA-Itraconazole for lung cancer and locally advanced and metastatic basal cell carcinoma (BCC). SUBA-Itraconazole has completed Phase II b clinical trials.
